Interviews profiling the chief executive officers of Australia's leading biotechnology companies by Biotech Daily editor, David Langsam, and focussing on their intellectual property, scientific research and development, market strategies and controversial issues facing their companies.

 

• ACRUX’S DR RICHARD TREAGUS:
  CRANKING THE HANDLE

• WHY DR RICHARD TREAGUS IS LEAVING ACRUX

• AVEXA’S DR JULIAN CHICK:
  A BIOTECH PARADIGM

• BIONOMICS' DR DEBORAH RATHJEN:
  'THIS IS JUST THE BEGINNING' 

• CHEMEQ’S DAVID WILLIAMS:
  FROM $8 TO 35c … AND BACK?

• CIRCADIAN'S DR MEGAN BALDWIN SHARPENS FOCUS

• CLINICAL CELL’S BOB ATWILL

• CLINUVEL’S DR PHILIPPE WOLGEN:
  ‘CUV1647 NOT COSMETIC NOT SUNBLOCK’

• CSIRO’S DR GRAEME WOODROW:
  ALL HAIL THE CHIEF

• EVOGENIX’S DR MERILYN SLEIGH:
  ‘KEEP IT SIMPLE’

• GBS VENTURE PARTNERS' DR GEOFF BROOKE:
  BUILDING AUSTRALIAN MEDICAL TECHNOLOGIES

• GENETIC TECHNOLOGIES' DR MERVYN JACOBSON:
  ‘ONE DECENT LICENCE AND WE’RE PROFITABLE’

• GENETIC TECHNOLOGIES DR PAUL MACLEMAN:
  THE HOTTEST SEAT IN BIOTECH

• GLAXOSMITHKLINE'S DEBORAH WATERHOUSE:
  NO ORDINARY BOSS

• IMPEDIMED'S GREG BROWN:
  'BRISBANE TO BASLE AND BACK'

• LEON SERRY: RETIREMENT STARTS WITH A 12-HOUR DAY

• MESOBLAST'S PROF SILVIU ITESCU: HE'S THE BOSS

• METABOLIC’S DR ROLAND SCOLLAY WON’T LOOK BACK

• MIPS' PROF BILL CHARMAN: FROM PHARMACY COLLEGE
  TO BIOTECH CRUCIBLE - PLUS

• NOVOGEN’S CHRIS NAUGHTON:
  ‘THE LONG WAIT FOR PHASE III RESULTS’

• PEPLIN’S MICHAEL ALDRIDGE:
  ‘CREDIBILITY IS CRITICAL’

• PEPLIN'S TOM WIGGANS - THIS ISN'T
  CANCER ANYMORE, TOTO

• PEPTECH’S DR JOHN CHIPLIN:
  ‘DOMAINS ARE THE CROWN JEWELS’

• PROTEOME STEPHEN PORGES: TESTING CANCER

• STARPHARMA'S DR JACKIE FAIRLEY:
  LEADER OF THE DENDRIMER PACK

• STEM CELL SCIENCES DR PETER MOUNTFORD:
  'PLAN R&D OR LOSE 20 YEARS'

• VICTORIA'S INNOVATION MINISTER
  MARTIN PAKULA TALKS BIOTECH

• WEHI'S PROF DOUG HILTON:
  EVOLUTION & VERY INTELLIGENT DESIGN